These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 12704813)
61. Inflammatory markers in AD and MCI patients with different biomarker profiles. Schuitemaker A; Dik MG; Veerhuis R; Scheltens P; Schoonenboom NS; Hack CE; Blankenstein MA; Jonker C Neurobiol Aging; 2009 Nov; 30(11):1885-9. PubMed ID: 18378357 [TBL] [Abstract][Full Text] [Related]
62. Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment. Riepe MW; Karl J; Tumani H; von Arnim CA Dement Geriatr Cogn Disord; 2010; 30(2):93-100. PubMed ID: 20720423 [TBL] [Abstract][Full Text] [Related]
63. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
64. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Riemenschneider M; Wagenpfeil S; Vanderstichele H; Otto M; Wiltfang J; Kretzschmar H; Vanmechelen E; Förstl H; Kurz A Mol Psychiatry; 2003 Mar; 8(3):343-7. PubMed ID: 12660807 [TBL] [Abstract][Full Text] [Related]
66. Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. Johansson P; Almqvist EG; Johansson JO; Mattsson N; Andreasson U; Hansson O; Wallin A; Blennow K; Zetterberg H; Svensson J PLoS One; 2013; 8(11):e81989. PubMed ID: 24312390 [TBL] [Abstract][Full Text] [Related]
67. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Atack JR; May C; Kaye JA; Kay AD; Rapoport SI Ann Neurol; 1988 Feb; 23(2):161-7. PubMed ID: 3377438 [TBL] [Abstract][Full Text] [Related]
68. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Nitsch RM; Deng M; Tennis M; Schoenfeld D; Growdon JH Ann Neurol; 2000 Dec; 48(6):913-8. PubMed ID: 11117548 [TBL] [Abstract][Full Text] [Related]
69. Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. Sáez-Valero J; Small DH J Alzheimers Dis; 2001 Jun; 3(3):323-328. PubMed ID: 12214053 [TBL] [Abstract][Full Text] [Related]
70. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type. Appleyard ME; McDonald B J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405 [TBL] [Abstract][Full Text] [Related]
71. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094 [TBL] [Abstract][Full Text] [Related]
72. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Wright CI; Geula C; Mesulam MM Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355 [TBL] [Abstract][Full Text] [Related]
73. Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type. Tune L; Gucker S; Folstein M; Oshida L; Coyle JT Ann Neurol; 1985 Jan; 17(1):46-8. PubMed ID: 3985585 [TBL] [Abstract][Full Text] [Related]
74. Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in Alzheimer's disease. Sáez-Valero J; Small DH Brain Res; 2001 Jan; 889(1-2):247-50. PubMed ID: 11166713 [TBL] [Abstract][Full Text] [Related]
75. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Thorsell A; Bjerke M; Gobom J; Brunhage E; Vanmechelen E; Andreasen N; Hansson O; Minthon L; Zetterberg H; Blennow K Brain Res; 2010 Nov; 1362():13-22. PubMed ID: 20875798 [TBL] [Abstract][Full Text] [Related]
76. [Biological marker for Alzheimer's disease]. Matsubara E Brain Nerve; 2010 Jul; 62(7):769-75. PubMed ID: 20675881 [TBL] [Abstract][Full Text] [Related]
78. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848 [TBL] [Abstract][Full Text] [Related]
79. The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Ballard C; Morris C; Kalaria R; McKeith I; Perry R; Perry E Dement Geriatr Cogn Disord; 2005; 19(5-6):357-60. PubMed ID: 15802910 [TBL] [Abstract][Full Text] [Related]
80. Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease. Huff FJ; Reiter CT; Protetch J Can J Neurol Sci; 1989 Nov; 16(4):406-10. PubMed ID: 2804802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]